MUC16 and ovarian carcinoma: Among the tools to evaluate progression and response to treatment, cancer antigen 125 (CA125) level is an important marker in epithelial ovarian cancer.5 The GCIG integrated the elevation of CA125 levels into the radiological Response Evaluation Criteria in Solid Tumours (RECIST) to give a combined definition of progression.6 These combined criteria have never, to our knowledge, been investigated as an OS surrogate using the meta-analytic approach.